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The prevalence of congenital malformations and cognitive disorders in children whose mothers took antiepileptic drugs in
pregnancy is increased, compared with the background rate. Not all such cases are due to teratogenic effects of the mother’s
treatment. Certain problems, including neonatal withdrawal symptons, some malformations, characteristics facial features and a
typical developmental and behavioural pattern may be indicators of a probable teratogenic event. We describe a set of diagnostic
criteria which may assist in defining which children are likely to have a fetal anticonvulsant syndrome. This may help future
research to identify risk factors which predispose to an adverse fetal outcome.
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Between 6 and 9 per cent of children exposed to
antiepileptic (or anticonvulsant) drugs in utero are
born with congenital malformations1, 2. A further pro-
portion have learning difficulties or behaviour prob-
lems3. Epilepsy is common, affecting about five out
of 1000 mothers, therefore a large number of children
are at risk. Any congenital malformations or cogni-
tive disorders arising in these circumstances may be
attributed to antiepileptic drug exposure, yet this at-
tribution is likely to be incorrect some of the time.
Certain malformation patterns are associated with par-
ticular drugs, such as neural tube defects with sodium
valproate and carbamazepine, fingernail hypoplasia
with carbamazepine and phenytoin, congenital heart
disease with all three, and each syndrome has a charac-
teristic face4–6. The diagnosis of a fetal anticonvulsant
syndrome may be straightforward when a recogniz-
able pattern of anomalies is seen, but it is not clear
how many anomalies must be present to constitute
one of the syndromes. In addition, it may be possible
for exposure to antiepileptic drugs to cause a charac-
teristic face, but a child’s microcephaly, for example,
may have some other cause. A distinction could be
drawn between fetal anticonvulsant effects and a fe-
tal anticonvulsant syndrome. To try to address these
problems, we developed draft diagnostic criteria based
on the model of the Marfan syndrome clinical diag-
nostic nosology7. This nosology was devised to help
overcome the lack of a reliable diagnostic test in that
disorder. Clinical signs in different body systems are
assessed, and a scoring system is applied based on
major and minor features. In a similar way, we consid-
ered the assessment of a child potentially affected by
an antiepileptic drug through six clinical problem ar-
eas (Table 1). Firstly, evidence of neonatal withdrawal
should be considered including jitteriness, feeding
disorder, hypoglycemia, hypotonia, and seizures. Sec-
ondly, the characteristic facial appearance should be
sought. This varies with age and with antiepileptic
drug, and although lists of features can be devised, it
is the overall gestalt which is important. Thirdly, the
presence of typical malformations should be noted.
These could be considered major if they are character-
istic of the antiepileptic drug in question (e.g. neural
tube defect for valproate or carbamazepine) or minor
if they are less typical (e.g. renal malformation), or
less objective (e.g. mild nail hypoplasia). Fourthly, the
occurrence of certain medical problems in later child-
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Table 1: Fetal anticonvulsant syndrome assessment.
Clinical problem area Typical features
Neonatal withdrawal Jittery, hypotonia, seizures, apnoeic episodes, hypoglycemia, feeding disorder
Characteristic facial appearance Telecanthus, epicanthic folds, infraorbital groove, convergent squint, broad or flat nasal bridge,
anteverted nares, broad or flat nasal tip in older children, shallow or smooth philtrum, thin upper
lip, micrognathis, broad or tall forehead, metopic ridging, low set posteriorly rotated ears,
overfolded helix, sometimes featureless helix
Congenital malformations Cardiac malformation, genital anomaly, neural tube defect, orofacial cleft, hypoplasia of fingers
or fingernails, toes or toenails, talipes equino-varus, other limb anomaly, congenital dislocation of
hip, hernia, craniosynostosis, upper airway malformation
Childhood medical problems Myopia, strabismus, otitis media with effusion requiring surgery, joint laxity
Neurodevelopment Typically communication disorder with speech and language delay, sometimes also gross motor
delay and/or fine motor delay
Behaviour Autism, Asperger syndrome, Attention deficit hyperactivity disorder, or behaviour problems
associated with attention deficit or communication disorder
Table 2: Diagnostic criteria.
1. History of in-utero antiepileptic drug exposure
2. Presence of characteristic facial appearance
3. Presence of at least one of the following
(a) evidence of neonatal withdrawal
(b) compatible malformation
(c) compatible childhood medical problem
(d) compatible developmental history
(e) compatible behavioural problem
4. Normal relevant investigations for alternative aetiologies
(e.g. karyotype, Fragile X mutation analysis,
CATCH22 deletion studies)
hood is of importance. In a recent study of patients
ascertained through the National Fetal Anticonvulsant
Syndrome Association, a high frequency of problems
such as joint laxity, myopia, and glue ear requiring
grommets was recorded. This may help make the di-
agnosis in an older child. In the same study, a charac-
teristic pattern of developmental delay was seen, par-
ticularly involving speech and language, and a pattern
of behaviour ranging from poor social skills to autism
at the extreme. Similar behavioural and learning dis-
orders have been previously described8. The fifth and
sixth areas are therefore neurodevelopment, and be-
haviour. At present, there are insufficient systematic
data to permit weighting of these features in a diagnos-
tic nosology. In the absence of a positive test for a fetal
anticonvulsant syndrome it is also important that other
causes of a child’s malformations, medical, learning
or behaviour disorders should be excluded. We sug-
gest the diagnosis could therefore be considered when
the four criteria shown in Table 2 are all met. Cer-
tain malformations may however be more specific than
others, and it would be unwise, for example, to dis-
miss antiepileptic drug exposure as a cause of an oth-
erwise isolated neural tube defect. As evidence accu-
mulates about the newer drugs such as gabapentin, vi-
gabatrin, topiramate and lamotrigine the features con-
sidered characteristic may change, and it is to be hoped
with improving therapies, the incidence of the fetal an-
ticonvulsant syndromes will diminish.
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